BioNano Genomics Inc vs Manchester United PLC — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Manchester United PLC trades at $22.23 (market cap $3.80B). The key difference: Manchester United PLC is far larger — about 278.2× BioNano Genomics Inc's market cap, and Manchester United PLC pays a 1.26% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MANU | |
|---|---|---|
Market Cap | $13.66M | $3.80B |
Sector | Health | Media |
52-Week High | $4.92 | $23.53 |
52-Week Low | $1.06 | $15.10 |
Enterprise Value | $16.26M | $4.74B |
Dividend Yield | — | 1.26% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Manchester United (MANU) trades at $22.88, up 5.44% on the day, with a bearish technical signal. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights the acquisition of land for a new 100,000-seat stadium as a significant long-term de-risking milestone. Cash flow from operations remains positive at $72.70M, but negative profitability metrics and high debt levels persist.
The outlook is mixed; stadium development and Champions League qualification offer growth catalysts, but consistent net losses and weak margins pose fundamental risks. Analyst consensus is neutral with a 60% hold rating. The stock's trajectory hinges on successful execution of cost reductions and capitalizing on new revenue streams from the stadium project.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →